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Summary. Somatostatin receptor (SS-R) scintigraphy has
been successfully used in the visualization of a variety of
neuroendocrine tumours. In vitro studies have shown that
SS-Rs are present in human malignant lymphomas. We
conducted a prospective study in 56 consecutive untreated
patients with histologically proven Hodgkin’s disease (HD)
and compared the results of SS-R scintigraphy with physical
and radiological examinations as initial evaluation.
SS-R scintigraphy was positive in 55/56 (98%) patients at
sites of documented disease. In 20 patients SS-R scintigraphy
disclosed lymphoma localizations not revealed following pro-
cedures of conventional staging. As a result in 12 patients
(21%) SS-R scintigraphy produced a change of stage and in
seven patients (13%) the additional information obtained
from SS-R scintigraphy led to a change of treatment. SS-R
scintigraphy failed to visualize sites of HD in four patients,
mainly in the abdominal area. In three patients a false-
positive result was obtained.
These data show that SS-R scintigraphy provides an imaging
technique that appears to visualize tumours in most patients
with HD and may be clinically useful in the management of
these patients.
Keywords: somatostatin, somatostatin receptor scintigraphy,
Hodgkin’s disease, octreotide, staging of Hodgkin’s disease.
Precise staging of the dissemination of the disease is critical in
the treatment and prognosis of patients with Hodgkin’s
disease (HD). To determine the extent of the disease, several
imaging techniques are currently employed, e.g. plain chest
radiography, computed tomography (CT), sonography and
lymphangiography (North & Jing, 1988). These techniques
are also used to assess the response of the disease at different
sites to treatment. Gallium scintigraphy is variably used in the
work-up of patients with HD (Front et al, 1995).
A variety of human neoplasms express somatostatin
receptors (SS-Rs). SS-Rs have been found in neuroendocrine
(Reubi et al, 1987, 1990a, c), breast (Reubi et al, 1990b;
van Eijck et al, 1994) and brain tumours (Reubi et al, 1986).
In order to take advantage of SS-R tissue expression, radio-
labelled somatostatin (SS) analogues have been applied to
visualize SS-R-positive tumours in vivo with a gamma-
camera. SS-R scintigraphy has proved clinically useful for
refined tumour localization in patients with carcinoid
tumours, pancreatic endocrine tumours and paragangliomas
(Krenning et al, 1989, 1995; Lamberts et al, 1990;
Kwekkeboom et al, 1993).
SS-Rs are expressed on the membranes of human lymphoid
cells, including malignant lymphoma and HD (Reubi et al,
1992), as has become apparent from autoradiography of
tissue sections. There is as yet only limited experience with
SS-R scintigraphy in patients with HD (Bares et al, 1993; van
Hagen et al, 1993; Bong et al, 1994; Lipp et al, 1995). We set
out to evaluate SS-R scintigraphy as a potentially useful
method for in vivo imaging of tumour deposits in patients with
HD. Here we present the results of a prospective study in 56
newly diagnosed, previously untreated, patients with histo-
logically proven HD.
PATIENTS AND METHODS
Patients. 56 consecutive, newly diagnosed and previously
untreated patients with histologically proven HD were
enrolled in the study. The stage of the disease according
to the Ann Arbor classification (Carbone et al, 1971) was
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established by conventional methods which included a
physical examination, chest radiography, CT of chest, abdo-
men and pelvis, bone marrow biopsy, and occasionally
lymphangiography. All patients had given informed consent
to the study, which was approved by the ethics committee of
the University Hospital Rotterdam.
Scintigraphy. SS-R scintigraphy was performed after intra-
venous injection of the radioactive labelled SS analogue
[111In-DTPA-D-Phe1]octreotide (obtained from Mallinckrodt
Medical BV, Petten, The Netherlands). The preparation of
[111In-DTPA-D-Phe1]octreotide, the dose administered (222 MBq)
and the technique of scintigraphy with the gamma-camera,
as well as with single photon emission computed tomography
(SPECT) have recently been described (Bakker et al, 1991;
Krenning et al, 1992, 1993, 1994, 1995). Planar total body
scintigraphy was performed 24 h post-injection with a large-
field-view gamma camera (Counterbalance 3700 and ROTA II;
Siemens Gammasonics, Erlangen, Germany) equipped with a
medium-energy collimator. In all patients SPECT images of
the upper abdomen were made. For both planar and SPECT
scintigraphy, images with a long exposure time were
obtained, e.g. 15 min for planar views. Repeat scintigraphy
of the abdomen was performed 48 h post-injection when 24 h
scintigraphy showed accumulation in the abdomen. In
normal individuals a physiological accumulation of radio-
activity may be seen at 24 h after intravenous administration
of [111In-DTPA-D-Phe1]octreotide in the pituitary and thyroid
gland, the liver, spleen, kidneys, the urinary bladder and
occasionally in the gall-bladder. The presence of intestinal
radioactivity (mainly in the colon at 24 h) is due to some
hepatobiliary clearance of [111In-DTPA-D-Phe1]octreotide
and may be reduced following the use of laxatives (Krenning
et al, 1992, 1993). The SS-R scans were evaluated by two
investigators at the same time without knowing patient
identity or results of the conventional diagnostic work-up.
Finally, the results of the SS-R scans and conventional
Table I. Clinical features and SS-R scintigraphy results
of 56 patients with HD.
Age (yr)
Median 33.1
Range 15–66
Sex
Female 29 (52%)
Male 27 (48%)
Histologic subtype
Lymphocyte predominance 4 (7%)
Nodular sclerosis 46 (82%)
Mixed cellularity 6 (11%)
Clinical stage*
Stage I 11 (19%)
Stage II 29 (52%)
Stage III 7 (13%)
Stage IV 9 (16%)
SS-R scintigraphy results
Positive 55 (98%)
Negative 1 (2%)
* Based on physical examination and conventional
staging methods.
Fig 1. (A) Visualization of mediastinal lymph nodes (arrow) in a patient with stage IB HD, mixed cellularity, by SS-R scintigraphy at 24 h (anterior
image of the thorax). On CT a large mediastinal mass of 11 9 cm was shown. In this patient normal accumulation of radioactivity in the thyroid,
not seen on this image, was apparent on the anterior image of the head and neck. (B) SS-R scintigraphy reveals positive supraclavicular lymph
nodes in the neck (arrow) at 24 h in a patient with stage IA HD, mixed cellularity (anterior image of the head and neck). Normal accumulation of
radioactivity is seen in the pituitary and thyroid. On physical examination a lymph node of 3 cm diameter was palpated.
diagnostic tests were compared by the study coordinator. In
case of discrepancies additional radiodiagnostic investigations
were scheduled before the beginning of treatment and, if
practically possible, cytological or histological verification was
sought. In nine patients SS-R scintigraphy was repeated after
therapy. All patients were followed during and after
treatment.
Autoradiography. In three patients SS-R autoradiography
was performed on 10m thick cryostat sections of tumour
samples, using a iodinated SS octapeptide analogue [125I-
Tyr3]octreotide (125I-204-090) as radioligand (Reubi et al,
1987, 1990a).
RESULTS
The clinical characteristics of the 56 patients with HD in
whom SS-R scintigraphy was performed are given in Table I.
SS-R scintigraphy indicated SS-R positivity at areas of
documented active disease in 55 cases (98%). Two examples
of SS-R scintigraphy of lymphoma localizations above the
diaphragm are shown in Fig 1A (mediastinum) and Fig 1B
(neck). In Figs 2A–C a SS-R scintigram of multiple para-aortic
abdominal lymph nodes is shown.
Additional sites of HD revealed by SS-R scintigraphy (20 patients)
In 20 patients SS-R scintigraphy disclosed activity suggestive
of lymphoma which had not been revealed following physical
and radiological examination. Table II lists the additional sites
of disease as suggested by SS-R scintigraphy in comparison
with the results of conventional staging in these 20 patients.
27 additional SS-R positive sites of disease became apparent in
these 20 patients. Most new localizations were above the
diaphragm, i.e. in the neck (n  12 cases), mediastinum
(n  3), axilla (n  3), infraclavicular area (n  1) and lung
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Fig 2. SS-R scintigraphy in a patient with
abdominal HD, nodular sclerosis. (A) Planar
anterior image of the abdomen at 48 h after
injection of [111In-DTPA-D-Phe1]octreotide.
Apart from normal accumulation of radioactivity
in the liver (L) and kidney (K) an enlarged spleen
(S) can be seen. Note the many sites of
accumulation of radiolabelled octreotide
(arrows), which represent para-aortic lymphoma
localizations. (B/C) Abdominal SPECT transversal
(B) and coronal (C) images of the same patient,
24 h after injection of
[111In-DTPA-D-Phe1]octreotide. Note the
visualization of the liver (L), spleen (S) and
kidneys (RK, LK). Clearly prominent hot spots are
seen medial/ventral to both kidneys in the para-
aortic region (PAO).
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(n  1), but also in the para-aortic region (n  5) and the
inguinal area (n  2). In patient 10, following the results of
SS-R scintigraphy, we confirmed the presence of an abnormal
lymph node in the neck on repeated palpation (1.5 cm
diameter). In the same patient multiple small intrapulmonal
‘lesions’ were seen on CT, which were read as possible
Hodgkin localizations. The intrapulmonal lesions were
negative on SS-R scintigraphy. After six cycles of chemo-
therapy no residual masses were seen. The radiographic
intrapulmonalabnormalitiesthat had been SS-R negative had
not changed and were retrospectively interpreted as pre-
existent abnormalities of unclear nature (follow-up time 2
years). In the majority of patients additional investigations
were performed to verify the diagnosis at discrepant sites (see
Table II). The superiority of SS-R scintigraphy was confirmed
in 12/20 patients, i.e. by repeated palpation (n  4),
subsequent radiodiagnostic tests (n  6) and/or cytopathol-
ogy (n  2). In the latter 12 patients the physical and
radiological abnormalities disappeared following cytotoxic
treatment (Table II, follow-up). In nine patients SS-R
scintigraphy was repeated after successful chemotherapy
and in all patients SS-R scintigraphy had become entirely
negative (Table II, repeated SS-R scintigraphy).
In 12 patients the discrepancies between SS-R scintigraphy
Table II. Additional sites of disease demonstrated following SS-R scintigraphy in 20/56 patients with HD: a
comparison between SS-R scintigraphy and conventional staging methods.
Change
Repeated SS-R clinical
Pt Additional sites of disease Verification (  HD) scintigraphy stage
2 Neck, para-aortic  CT, follow-up n.d. II ! III
4 Neck n.d. n.d. No
5 Neck  cytology, follow-up n.d. No
6 Neck  physical examination, follow-up n.d. No
8 Neck, mediastinum  CT, follow-up n.d. I ! II
10 Neck, lung negative  physical examination, follow-up n.d. IV ! II
13 Para-aortic  Yes II ! III
14 Neck n.d. n.d. No
17 Neck  sonography, follow-up n.d. No
20 Mediastinum, axilla, lung  Yes III ! IV
25 Para-aortic n.d. n.d. II ! III
27 Infraclavicular  CT, follow-up n.d. I ! II
28 Neck, mediastinum  CT, follow-up n.d. I ! II
29 Neck  Yes No
33 Neck, axilla, inguinal  physical examination, follow-up Yes No
35 Neck  Yes I ! II
44 Axilla  physical examination, follow-up Yes No
50 Para-aortic  CT, follow-up Yes II ! III
52 Para-aortic  Yes II ! III
55 Inguinal  histology, follow-up Yes II ! III
Table III. False-negative SS-R scintigraphy in 4/56 patients with HD: a comparison between SS-R scintigraphy and
conventional staging methods.
Clinical stage:
Sites of disease: conventional Sites of disease: Clinical stage:
Pt conventional methods methods SS-R scintigraphy SS-R scintigraphy
3 Left neck, mediastinum, IV Left neck, mediastinum, IV
lung, para-aortic lung
7 Left neck, mediastinum, III Left neck, mediastinum II
para-aortic
26 Mediastinum, para-aortic, III Left neck, mediastinum, III
spleen spleen
40 Mediastinum, para-aortic, III Mediastinum, para-aortic, III
left para-iliac, left inguinal, left para-iliac, left inguinal
spleen
and conventional staging procedures resulted in a change of
Ann Arbor clinical stage. SS-R scintigraphy findings correctly
upgraded the clinical stage in 11 cases and the clinical stage
was correctly downgraded in one patient. As a result the
treatment plan was altered in seven patients. In all seven
patients the superiorityof SS-R scintigraphy was supported by
additional evidence.
False-negative results of SS-R scintigraphy (four patients)
In four patients SS-R scintigraphy did not show localizations
which had become apparent following radiological methods
(see Table III). In patients 3, 7 and 26 enlarged abdominal
para-aortic lymph nodes visualized on CT and lymphangio-
graphy were not apparent on SS-R scintigraphy images.
The largest non-visualized lesion in the abdominal area had
a diameter of 4.5 cm. In all three patients the enlarged
para-aortic lymph nodes disappeared after treatment. In
the fourth patient (40), SS-R scintigraphy demonstrated a
normal-sized spleen with a homogenous distribution of
radioactivity, but CT and sonography showed a spleen
of normal size with multiple hypodense areas, which dis-
appeared following chemotherapy. In these four patients in
whom SS-R scintigraphy missed certain localizations of HD,
the clinical stage, if based on SS-R scintigraphy only, would
have been underestimated in one individual.
Spleen and abdominal lymph node involvement with HD
What about the performance of SS-R scintigraphy with
regards to abdominal involvement with HD? The spleen was
enlarged in seven patients according to CT and sonography. In
five of these individuals multiple hypodense areas were also
apparent (see Table IV). In all seven patients SS-R scinti-
graphy showed an enlarged spleen with a homogenous
distribution of radioactivity. In an eighth patient (no. 40),
where CT and sonography showed multiple hypodense areas
in a normal-sized spleen, the spleen appeared normal on SS-R
scintigraphy. Therefore SS-R scintigraphy failed to demon-
strate spleen involvement in one patient. Enlarged abdominal
para-aortic lymph nodes were seen on CT and lymphangio-
graphy in eight patients, five of whom were also SS-R
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Table IV. Abdominal lymph node or spleen involvement in HD: a
comparison between SS-R scintigraphy and conventional staging
methods (CSM).
SS-R scinti- SS-R scinti- SS-R scinti-
graphy/ graphyÿ/ graphy/
Sites of disease CSM CSM CSMÿ
Para-aortic 5 3 5
Spleen 7 1 –
Total 12 4 5
SS-R scintigraphy, somatostatin receptor scintigraphy; CSM, con-
ventional staging methods. SS-R scintigraphy/CSM : abnormali-
ties visualized by SS-R scintigraphy and CSM; SS-R scintigraphyÿ/
CSM : abnormalities visualized only by CSM; SS-R scintigraphy/
CSMÿ : abnormalities visualized only by SS-R scintigraphy. Numbers
indicate patients with para-aortic or spleen abnormalities that were
evident on SS-R scintigraphy and CSM.
Table V. False-positive SS-R scintigraphy in 3/56 patients with HD: a comparison between SS-R scintigraphy and conventional
staging methods.
Clinical stage:
Sites of disease: conventional Sites of disease: Reason false-positive
Pt conventional methods methods SS-R scintigraphy SS-R scintigraphy
42 Right neck, left/right axilla, II Right neck, left/right axilla, Ethmoidal sinusitis
mediastinum mediastinum, nasal region
46 Left neck, mediastinum II Left neck, mediastinum, Haematoma
anterior iliac spine
49 Left/right neck, mediastinum II Left/right neck, mediastinum Common cold
nasal region
Table VI. Concordance between SS-R scintigraphy and
conventional staging methods in 28/56 patients with HD.
No. of Clinical
patients Sites of disease stage
13 Neck, mediastinum II
4 Neck I
4 Neck, axilla, mediastinum II
2 Mediastinum I
1 Neck, bone marrow* IV
1 Neck, axilla, mediastinum, III
para-aortic
1 Neck, mediastinum, III
para-aortic, spleen
1 Neck, mediastinum, lung IV
1 Neck, axilla, inguinal, IV
mediastinum, para-aortic,
spleen, lung
* Bone marrow involvement not apparent on SS-R
scintigraphy.
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scintigraphy positive (see Table IV). The smallest lymphoma
within the abdomen demonstrated by SS-R scintigraphy had
a diameter of approximately 2.0 cm. In five other patients
para-aortic lymph nodes were visualized on SS-R scintigraphy
that had not been detected on CT and lymphangiography. In
three of these five patients the para-aortic SS-R-positive
lesions disappeared after chemotherapy. In the other two
patients SS-R scintigraphy was not repeated. One patient had
enlarged parailiac lymph nodes on CT and these were also
visualized by SS-R scintigraphy.
False-positive results of SS-R scintigraphy (three patients)
In three patients the positivity on SS-R scintigraphy on
selected sites clearly was not related to localizationsof HD (see
Table V). In two patients accumulation of radioactivity was
observed in the nasal region. A sinusitis in one patient and a
common cold in the other patient had caused the positive
scan. The third patient showed abnormal accumulation of
radioactivity in the anterior iliac spine after a bone marrow
biopsy at that site.
Further results of SS-R scintigraphy and SS-R autoradiography
In 28/55 SS-R-positive patients the results of SS-R scinti-
graphy and conventional staging methods were concordant.
The sites of disease and clinical stages are summarized in Table
VI. The smallest lymph node identified by SS-R scintigraphy
located in the neck had a diameter of 1.0 cm. The only patient
with an entirely negative SS-R scintigraphy had stage IVB HD
with lymph nodes in the axilla and an infiltrated bone
marrow.
Finally, side-effects were not noted in any of the patients
following the administration of [111In-DTPA-D-Phe1]octreo-
tide for SS-R scintigraphy.
In three patients SS-R analysis was performed on surgically
removed lymph nodes. Autoradiographic investigation con-
firmed the presence of specific SS-Rs in the tissue biopsies of
malignant lymphoma in these individuals (Figs 3A–C). These
lymph nodes were all positive in vivo on SS-R scintigraphy.
DISCUSSION
The accuracy of staging is a cornerstone of the treatment of
patients with HD. Clearly, current staging is still highly
inadequate. For instance, stage I and II patients considered at
high risk of failure are frequently treated with systemic
chemotherapy. For this purpose, in stages I and II, clinical
prognostic factors are employed to select between loco-
regional or systemic therapy. Following treatment it may
be difficult to distinguish between persisting active HD or
fibrotic abnormalities, e.g. in case of residual radiological
mediastinal masses still apparent following chemotherapy.
In the present study we employed SS-R scintigraphy in 56
consecutive patients with histologically proven HD. Among
these, 98% of the patients showed a positive SS-R scan. SS-R-
positive localizations were apparent at different sites of active
disease above and below the diaphragm. Since the pathophy-
siological basis of SS-R scintigraphy staging bears no
relationship to that of the other diagnostic imaging techni-
ques, SS-R scintigraphy appears to provide an independent
approach to the evaluation of the dissemination of HD.
Therefore SS-R scintigraphy may add essential information to
the results of the complete staging process. The discrepancies
between the results of SS-R scintigraphy and conventional
staging work-up as reported here support this. In only 28
patients was complete concordance apparent between SS-R
scintigraphy and physical examination, X-ray examination,
CT scanning and lymphangiography.
Autoradiography demonstrated the presence of SS-Rs in
the lymphoma tissues surgically removed from three patients
with HD. [111In-DTPA-D-Phe1]octreotide and [125I-Tyr3]-
Fig 3. Somatostatin receptors in a case of Hodgkin’s lymphoma.
(A) Haematoxylin–eosin-stained section. Bar1 mm. (B) Autoradio-
gram showing total binding of 125I-[Tyr3]octreotide. (C) Autoradio-
gram showing nonspecific binding of 125I-[Tyr3]octreotide (in
presence of 10ÿ6 M of unlabelled [Tyr3]octreotide).
octreotide bind with high affinity and specificity to the same
receptor (Bakker et al, 1991). The identification of SS-Rs
in vitro in biopsies from the lymph nodes with HD, confirms
that the activity seen in vivo actually represented SS-R-
positive tumour tissue. In patients with histologically proven
HD the tumours display SS-Rs of high enough affinity and
density to apparently permit external imaging by the
radiolabelled SS analogue in most cases.
In 20 patients SS-R scintigraphy disclosed lesions not
revealed following a variety of radiodiagnostic procedures.
In most of these individuals additional investigations were
undertaken in an effort to verify the diagnosis of HD at
sites of discrepancy.
SS-R scintigraphy failed to demonstrate certain sites of HD
in four cases and SS-R scintigraphy was entirely negative
in one individual with extensive involvement of HD. In a
significant proportion of cases the clinical stage as defined by
conventional staging methods changed following considera-
tion of the results of SS-R scintigraphy. In 11 cases of the
entire series of 56 subjects the disease was upgraded to a
higher stage. The additional information of SS-R scintigraphy
resulted in a different choice of therapy in seven patients
(13%).
As compared with conventional staging methods, SS-R
imaging offers a number of distinct advantages. First, because
the whole body is imaged, localizations in areas not under
clinical suspicion can be evaluated, and therefore the full
extent of the disease more accurately documented. Second,
after treatment with chemo- or radiotherapy, residual or
recurrent tumours of malignant lymphomas remain SS-R
positive (Reubi et al, 1992). SS-R scintigraphy may be
potentially useful to assess remission and avoid ‘over
treatment’ in patients in remission. SS-R scintigraphy may
also be of use in the management of residual masses,
including the notoriously difficult mediastinal localizations.
Our preliminary experience in two patients with primary
resistant HD gives some support that this may be true (data
not shown). After six cycles of chemotherapy a residual mass
was seen on CT in the mediastinum in one patient and in the
para-aortic region of the abdomen in the second. SS-R
scintigraphy was positive in these areas in both patients.
Histologic confirmation of active HD at the latter sites was
obtained in both patients. We are presently investigating the
role of SS-R scintigraphy in the evaluation of treatment
response in patients with HD in a prospective study.
In the abdominal region SS-R scintigraphy (unlike
conventional techniques) revealed para-aortic lymph nodes
in five patients. A repeated SS-R scintigraphy after chemo-
therapy in three of these patients showed total disappearance
of the lesions. In 12 cases there was complete agreement
between the results of SS-R scintigraphy and conventional
radiodiagnostictechniques in the detection of abdominal sites
of HD. SS-R scintigraphy failed to detect abdominal HD in four
patients. Para-aortic lymph nodes were missed in three
patients and spleen involvement was not apparent on SS-R
scintigraphy in one patient. Thus, all false-negative cases of
our series were located in the abdomen. This problem was
also seen in patients with carcinoid tumours where planar
images of SS-R scintigraphy failed to detect some liver
metastases (Kwekkeboom et al, 1993). The visualization of
abdominal lymphoma localizations with [111In-DTPA-D-
Phe1]octreotide may be limited by a number of factors. The
human spleen expresses high-affinity SS-Rs (Reubi et al,
1993). Frequently lymphoma metastases in the spleen appear
to accumulate a similar amount of radioactivity as does
surrounding normal spleen tissue. After intravenous injec-
tion, [111In-DTPA-D-Phe1]octreotide is rapidly cleared from
the blood, predominantly excreted via the kidneys, and a
minority of the isotope removed by hepatobiliary clearance
(Krenning et al, 1992). The hepatobiliary clearance results in
hepatic and intestinal accumulation of radioactivity. The
presence of intestinal radioactivity can usually be overcome
by the use of laxatives. Nevertheless, in some patients
radioactivity may remain in the colon and this may interfere
with the detection of para-aortic lymph nodes. The physio-
logical uptake of radioactivity in the liver, although less than
in the spleen, may reduce optimal detection of liver
involvement with SS-R-positive tumours. Overprojection of
radioactivity of the liver, spleen and kidneys can hide positive
lesions in lymph nodes on the planar images. The use of
SPECT images of the upper abdomen in part may overcome
this problem and is therefore recommended for the localiza-
tion of abnormal lymph nodes in the spleen and liver hilar
areas. The same is true for the para-aortic region of the upper
abdomen.
SS-R scintigraphy is not specific for visualizing tissue
involved with HD. Granulomatous diseases, autoimmune
diseases and neuroendocrine tumours may result in positive
SS-R scintigraphy images as well (Krenning et al, 1993;
Vanhagen et al, 1994). Obviously, therefore, SS-R scinti-
graphy cannot be used to diagnose malignant lymphoma. In
this respect, SS-R scintigraphy shares the general limitations
of most imaging techniques. In our study, three false-positive
results were seen. In two cases the positivity in the nasal
region on the scan was caused by an infection; clinically, these
two patients had a common cold. This transient accumula-
tion in the nasal region during the typical season of epidemic
common cold/influenza is a well-known pitfall in the correct
interpretation of SS-R scintigraphy (Krenning et al, 1993).
The third patient showed accumulation of radioactivity in the
pelvis after bone marrow biopsy. Clinically a large haematoma
was apparent. Our accumulated experience in more than a
thousand patients has taught us that radioactivity may
accumulate at sites of recent operation.
In several centres gallium scintigraphy is used in the work-
up of HD patients. Gallium scintigraphy is performed prior to
therapy to provide information on the gallium avidity of the
tumour at baseline. Current evidence would indicate that the
sensitivity of gallium scintigraphy in the initial staging of
patients with HD is in the order of 66–85% (Front et al, 1990;
Hagemeister et al, 1990). The most important value of
gallium scintigraphy is therefore not in the initial staging of
patients with HD but rather in the evaluation of lymphoma
after treatment (Front et al, 1995). It would be of interest to
compare SS-R scintigraphy and gallium scintigraphy in the
staging of HD in future studies. In this age of financial
restraint these imaging techniques should be cost-effective. In
Rotterdam a prospective cost-effective study is currently in
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progress that includes ultrasonography, computed tomogra-
phy, galliumscintigraphy and SS-R scintigraphy.
In conclusion, SS-R scintigraphy provides a useful method
of diagnostic evaluation of patients with HD. It is a relatively
easy and harmless procedure. Obviously, further prospective
studies in larger groups of patients, both pre- and post-
treatment, will be needed to fully define its value and place in
the management of patients with HD.
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